

Cardiac biomarkers: a contemporary status report

Alan S Maisel, Vikas Bhalla and Eugene Braunwald

Nature Clinical Practice Cardiovascular Medicine (2006) **3**: 24–34 [doi:10.1038/ncpcardio0405]

doi:10.1038/ncpcardio0514

CORRIGENDUM

In the January 2006 issue, the footnote to Table 1 was published as “^aN-terminal pro-brain natriuretic peptide has yet to be approved by the FDA for risk-stratification purposes in acute coronary syndromes”. This should have

appeared as “^aN-terminal pro-brain natriuretic peptide has been approved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for risk-stratification purposes in patients with stable coronary artery disease”.

Table 1 The usefulness of inflammatory biomarkers in diagnosis and risk stratification in acute coronary syndromes.

	Biomarker						
	CK-MB	cTnI/T	hsCRP	BNP/ NT-proBNP	IMA	MPO	CD40L
Diagnosis	Yes	Yes	No	No	Yes	Result unclear	No
Outcomes	Death	Death/ MI/RI	Death/MI/ RI	Death/CHF	No	Death/MI	Death/MI
Short term	Yes	Yes	Yes	Yes	—	Yes	Yes
Long term	Yes	Yes	Yes	Yes	—	Yes	Yes
Independent	Yes	Yes	Yes	Yes	—	Yes	Yes
FDA approval	Yes	Yes	Yes	Yes ^a	Yes	No	No
Guidelines	Class I	Class I	Class IIa	Yes	No	No	No

^aN-terminal pro-brain natriuretic peptide has been approved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for risk-stratification purposes in patients with stable coronary artery disease. BNP, brain natriuretic peptide; CD40L, CD40 ligand; CHF, congestive heart failure; CK-MB, creatine kinase MB; cTnI/T, cardiac troponin I or T; hsCRP, high-sensitivity C-reactive protein; IMA, ischemia-modified albumin; MI, myocardial infarction; MPO, myeloperoxidase; NT-proBNP, N-terminal pro-brain natriuretic peptide; RI, recurrent infarction.